Recombinant IL17A (Vunakizumab Biosimilar) antibody

Catalog No. ABIN7488115

The Mammalian Cells Monoclonal anti-IL17A (Vunakizumab Biosimilar) antibody is suitable to detect IL17A (Vunakizumab Biosimilar) in samples from Human. It has been validated for ELISA.

Quick Overview for Recombinant IL17A (Vunakizumab Biosimilar) antibody (ABIN7488115)

Target: IL17A (Vunakizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This IL17A (Vunakizumab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-IL17A (Vunakizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Vunakizumab Biosimilar - Anti-IL17A mAb

Characteristics: Antibody Type: IgG1-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1 kappa

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for IL17A (Vunakizumab Biosimilar)

Target: IL17A (Vunakizumab Biosimilar)

Target Type: Biosimilar

Background: SHR-1314
Vunakizumab is a recombinant humanized IgGκ monoclonal antibody binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A).

CAS-No: 1792181-33-9